IN2015DN00914A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00914A
IN2015DN00914A IN914DEN2015A IN2015DN00914A IN 2015DN00914 A IN2015DN00914 A IN 2015DN00914A IN 914DEN2015 A IN914DEN2015 A IN 914DEN2015A IN 2015DN00914 A IN2015DN00914 A IN 2015DN00914A
Authority
IN
India
Prior art keywords
methods
etk
txk
bmx
itk
Prior art date
Application number
Other languages
English (en)
Inventor
Xiao Xu
Xiaobo Wang
Long Mao
Li Zhao
Biao Xi
Original Assignee
Acea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/843,554 external-priority patent/US9034885B2/en
Application filed by Acea Biosciences Inc filed Critical Acea Biosciences Inc
Publication of IN2015DN00914A publication Critical patent/IN2015DN00914A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
IN914DEN2015 2012-08-06 2013-07-11 IN2015DN00914A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261680231P 2012-08-06 2012-08-06
US13/843,554 US9034885B2 (en) 2012-01-13 2013-03-15 EGFR modulators and uses thereof
US201361814147P 2013-04-19 2013-04-19
US13/917,514 US8685988B2 (en) 2012-08-06 2013-06-13 EGFR modulators and uses thereof
PCT/US2013/050163 WO2014025486A1 (en) 2012-08-06 2013-07-11 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
IN2015DN00914A true IN2015DN00914A (ru) 2015-06-12

Family

ID=50068479

Family Applications (1)

Application Number Title Priority Date Filing Date
IN914DEN2015 IN2015DN00914A (ru) 2012-08-06 2013-07-11

Country Status (22)

Country Link
EP (2) EP3170825B1 (ru)
JP (2) JP6215938B2 (ru)
KR (1) KR102181365B1 (ru)
CN (2) CN103748096B (ru)
AU (1) AU2013300106B2 (ru)
BR (1) BR112015002709B1 (ru)
CA (1) CA2881275C (ru)
CY (1) CY1120844T1 (ru)
DK (1) DK2880035T3 (ru)
ES (2) ES2733576T3 (ru)
HK (1) HK1210471A1 (ru)
HR (1) HRP20170311T1 (ru)
HU (1) HUE031955T2 (ru)
IN (1) IN2015DN00914A (ru)
LT (1) LT2880035T (ru)
MX (1) MX361992B (ru)
NZ (1) NZ629807A (ru)
PT (1) PT2880035T (ru)
RU (2) RU2018104702A (ru)
SG (1) SG11201500872SA (ru)
WO (1) WO2014025486A1 (ru)
ZA (2) ZA201500762B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3409278T3 (da) 2011-07-21 2020-11-09 Sumitomo Dainippon Pharma Oncology Inc Heterocykliske proteinkinaseinhibitorer
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CA2861010A1 (en) * 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
BR112015016997A2 (pt) * 2013-01-16 2017-07-11 Signal Pharm Llc composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
JP6433974B2 (ja) * 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
WO2015006754A2 (en) 2013-07-11 2015-01-15 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016130920A2 (en) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
JP6457697B2 (ja) 2015-04-29 2019-01-23 カントン チョンション ファーマシューティカル カンパニー，リミティド キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
RU2018115334A (ru) 2015-10-09 2019-11-11 Ацея Терапьютикс, Инк. Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663208B (zh) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
CN107663207B (zh) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107955019B (zh) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
JP7164203B2 (ja) 2017-02-08 2022-11-01 中国医▲薬▼研究▲開▼▲発▼中心有限公司 ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途
JP2020516682A (ja) * 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
MX2020010437A (es) 2018-04-05 2021-01-29 Sumitomo Pharma Oncology Inc Inhibidores de axl cinasa y uso de los mismos.
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
WO2021093839A1 (zh) * 2019-11-13 2021-05-20 南京明德新药研发有限公司 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN115611989B (zh) * 2022-10-09 2023-08-01 武汉理工大学 机械活化淀粉衍生物抑制剂的优化制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563905A (en) 1992-09-24 1996-10-08 Hughes Aircraft Company Network communication system having time-sliced protocol
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
WO2005047482A2 (en) 2003-11-12 2005-05-26 Xiao Xu Real time electronic cell sensing systems and applications for cell-based assays
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
JP4745056B2 (ja) 2002-07-20 2011-08-10 アセア バイオサイエンシーズ，インク． インピーダンスによる細胞と微粒子の測定装置及び方法
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
BRPI0617167B8 (pt) * 2005-09-21 2021-05-25 Nycomed Gmbh sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
MX361992B (es) 2018-12-19
HUE031955T2 (en) 2017-08-28
EP3170825B1 (en) 2019-04-10
RU2015107831A (ru) 2016-09-27
LT2880035T (lt) 2017-03-27
CA2881275C (en) 2020-10-20
EP2880035B1 (en) 2016-12-07
CN107266453B (zh) 2020-02-07
AU2013300106B2 (en) 2017-11-30
ZA201500762B (en) 2021-09-29
HRP20170311T1 (hr) 2017-04-21
RU2645672C2 (ru) 2018-02-27
HK1210471A1 (en) 2016-04-22
CN107266453A (zh) 2017-10-20
ES2733576T3 (es) 2019-12-02
EP2880035B9 (en) 2017-05-17
SG11201500872SA (en) 2015-03-30
CN103748096B (zh) 2017-10-20
JP6215938B2 (ja) 2017-10-18
NZ629807A (en) 2017-04-28
PT2880035T (pt) 2017-03-10
WO2014025486A1 (en) 2014-02-13
KR102181365B1 (ko) 2020-11-23
ZA201600648B (en) 2021-09-29
JP2017061581A (ja) 2017-03-30
BR112015002709B1 (pt) 2022-09-20
EP2880035A1 (en) 2015-06-10
DK2880035T3 (en) 2017-03-06
CY1120844T1 (el) 2019-12-11
ES2618007T3 (es) 2017-06-20
CN103748096A (zh) 2014-04-23
CA2881275A1 (en) 2014-02-13
AU2013300106A1 (en) 2015-02-19
KR20150068949A (ko) 2015-06-22
RU2018104702A (ru) 2019-02-22
MX2015001715A (es) 2015-07-06
BR112015002709A2 (pt) 2017-07-04
EP3170825A1 (en) 2017-05-24
JP2015524468A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
IN2015DN00914A (ru)
MX2018004332A (es) Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
NZ715687A (en) Pyrimidine derivatives as kinase inhibitors
MX347040B (es) Inhibidores de tirosina-cinasas.
PH12016500531B1 (en) Compound inhibiting activities of btk and/or jak3 kinases
MY159327A (en) Jak kinase modulating quinazoline derivatives and methods of use thereof
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
GEP20156333B (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
EA201691930A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
WO2012030944A3 (en) Quinoline and isoquinoline derivatives for use as jak modulators
NZ703343A (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
BR112015000459A2 (pt) inibidores da enzima fosfodiesterase 10
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
CY1122837T1 (el) Θεραπεια της γυροειδους αλωπεκιας
CY1115157T1 (el) Παραγωγα κιναζολινης ρυθμιστικα της κινασης jak και μεθοδοι χρησεως αυτων